GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (LTS:0RHR) » Definitions » PB Ratio

Kuros Biosciences (LTS:0RHR) PB Ratio : 11.62 (As of Apr. 09, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Kuros Biosciences PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-09), Kuros Biosciences's share price is CHF18.02952. Kuros Biosciences's Book Value per Share for the quarter that ended in Dec. 2024 was CHF1.55. Hence, Kuros Biosciences's PB Ratio of today is 11.62.

The historical rank and industry rank for Kuros Biosciences's PB Ratio or its related term are showing as below:

LTS:0RHR' s PB Ratio Range Over the Past 10 Years
Min: 0.27   Med: 0.93   Max: 18.03
Current: 11.66

During the past 13 years, Kuros Biosciences's highest PB Ratio was 18.03. The lowest was 0.27. And the median was 0.93.

LTS:0RHR's PB Ratio is ranked worse than
96.2% of 790 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs LTS:0RHR: 11.66

During the past 12 months, Kuros Biosciences's average Book Value Per Share Growth Rate was 0.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -12.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -14.20% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Kuros Biosciences was 26.60% per year. The lowest was -50.80% per year. And the median was -19.80% per year.

Back to Basics: PB Ratio


Kuros Biosciences PB Ratio Historical Data

The historical data trend for Kuros Biosciences's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kuros Biosciences PB Ratio Chart

Kuros Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.80 0.85 0.80 2.26 13.84

Kuros Biosciences Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.76 2.26 7.31 13.84

Competitive Comparison of Kuros Biosciences's PB Ratio

For the Medical Devices subindustry, Kuros Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kuros Biosciences's PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's PB Ratio falls into.


;
;

Kuros Biosciences PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Kuros Biosciences's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=18.02952/1.551
=11.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Kuros Biosciences  (LTS:0RHR) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Kuros Biosciences PB Ratio Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kuros Biosciences Business Description

Traded in Other Exchanges
Address
Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of inventive products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategies.

Kuros Biosciences Headlines

No Headlines